Seres Therapeutics Inc (NASDAQ:MCRB) – Jefferies Financial Group issued their Q1 2019 EPS estimates for shares of Seres Therapeutics in a research note issued on Tuesday, April 30th. Jefferies Financial Group analyst C. Howerton forecasts that the biotechnology company will post earnings of ($0.50) per share for the quarter. Jefferies Financial Group has a “Hold” rating and a $7.00 price objective on the stock. Jefferies Financial Group also issued estimates for Seres Therapeutics’ Q2 2019 earnings at ($0.40) EPS, Q3 2019 earnings at ($0.60) EPS, Q4 2019 earnings at ($0.60) EPS, FY2019 earnings at ($2.10) EPS, FY2020 earnings at ($2.50) EPS, FY2021 earnings at ($3.60) EPS, FY2022 earnings at ($4.80) EPS and FY2023 earnings at ($5.00) EPS.
Several other equities analysts also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Seres Therapeutics in a report on Friday. BidaskClub downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Seres Therapeutics in a report on Thursday. ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 27th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Tuesday, March 19th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $11.21.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.12). Seres Therapeutics had a negative net margin of 350.03% and a negative return on equity of 1,584.13%. The firm had revenue of $7.32 million for the quarter, compared to analyst estimates of $8.61 million.
Hedge funds have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its holdings in Seres Therapeutics by 945.5% in the first quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 3,924 shares during the period. Great West Life Assurance Co. Can acquired a new stake in Seres Therapeutics in the fourth quarter worth about $30,000. Two Sigma Investments LP acquired a new stake in Seres Therapeutics in the fourth quarter worth about $82,000. Rhumbline Advisers lifted its holdings in Seres Therapeutics by 48.8% in the fourth quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 8,895 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Seres Therapeutics by 7.6% in the fourth quarter. Bank of New York Mellon Corp now owns 85,364 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 6,023 shares during the period. 77.26% of the stock is owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
See Also: What is channel trading?
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.